Omya will be presenting its functionalized calcium carbonate for several applications at the show.
At CPhI 2017 in Frankfurt, Omya will showcase its Omyapharm multifunctional excipient platform based on functionalized calcium carbonate, a highly structured mineral. Omyapharm has applications in solid oral dosage forms such as conventional tablets and capsules, microencapsulated products, and fast disintegrating formulations. The company will also present its active pharmaceutical ingredients Omyapure and Omya-Cal, natural calcium carbonates for dietary supplements, antacids, and osteoporosis treatments.
Omyapharm 500-OG is a fine powder consisting of calcium carbonate and tribasic calcium phosphate. It is suitable for wet and dry granulation as well as for hot-melt extrusion. Omyapharm 500-DG OG, meanwhile, is the granulated form of Omyapharm 500-OG and contains a superdisintegrant. Because of its special granulation, Omyapharm 500-DG OG offers improved flowability and can be directly compressed into tablets.
Omyapharm 500-DG OG has special importance when it comes to orally dispersible tablets (ODTs) and granules (ODGs). Its high porosity and specific surface properties enable fast disintegration and good compactibility that results in harder tablets at low compression forces. Tablets formulated with the functionalized calcium carbonate can be filled in conventional packaging because of their mechanical strength, thus reducing costs and difficulties during the conditioning process. ODTs manufactured from this excipient disintegrate in less than 10s. At Omya’s booth, CPhI visitors will be able to see flavored ODT samples and experience their fast disintegration properties.
Omya will also showcase its natural calcium carbonates Omyapure and Omya-Cal. Natural calcium carbonate is a high-purity calcium source with 40% bioavailable calcium. It is a valuable ingredient for calcium supplementation-for instance, to treat conditions such as osteoporosis-and for antacid formulations to neutralize stomach acid.
Source: Omya, Booth 102D112
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.